Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New CLL Treatment Paradigm Nears In EU For AbbVie

EMA OKs New Indication For Venclyxto

Executive Summary

The first chemotherapy-free, first-line treatment for chronic lymphocytic leukemia where dosing can be completed in one year has received the thumbs up by the European Medicines Agency.

You may also be interested in...



EU Firsts Beckon For Alnylam & Novo; Wins For A Raft Of Others

A plethora of new drugs moved closer to the EU market this week after the European Medicines Agency recommended that they should be approved.

Faster Please: Alnylam, Eiger & BioCryst Want Quick EMA Reviews

Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.

New Indications For Diabetes Drugs Under The Spotlight At EMA

Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel